The board of directors (the "Board" or the "Directors") of Clearbridge Health Limited refers to the announcements of the Company dated 27 March 2020, 3 April 2020, 26 May 2020, 24 December 2021, 24 June 2022, 23 September 2022, 28 February 2023, 10 March 2023, 22 September 2023, 4 October 2023, 22 November 2023 and 23 November 2023 (the "Announcements"). All capitalised terms used and not defined in this announcement shall have the same meanings ascribed to them in the Announcements. In particular, the Company refers to its announcement dated 23 November 2023 where it stated that CBSA had entered into a Second Partial Settlement Deed, pursuant to which Biolidics agreed that the Final Outstanding Debt of SGD 1,338,750, shall be payable by Biolidics to CBSA by the Extended Final Repayment Date, being within two (2) days following the date of receipt of proceeds from the Investor or by 23 December 2023, whichever is earlier.

The Company wishes to announce that CBSA has received the full amount of the Final Outstanding Debt on 30 November 2023 and in consideration of this, CBSA has entered into a deed of release of the Charged Shares in favour of Biolidics on the same day. Accordingly, no further amounts are owing by Biolidics to CBSA.